Sutro Biopharma (STRO) Long-Term Investments (2019 - 2022)

Sutro Biopharma has reported Long-Term Investments for 4 years, with the latest figure at $20.7 million in Q1 2022.

• Quarterly Long-Term Investments fell 72.25% year-over-year to $20.7 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $20.7 million (down 72.25% YoY) and the FY2021 annual result came in at $68.8 million, changed N/A from the prior year.
• Long-Term Investments eased to $20.7 million in Q1 2022 per STRO's latest filing, from $68.8 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $74.6 million in Q1 2021 and troughed at $5.6 million in Q2 2020.
• A 4-year average of $34.3 million and a median of $20.7 million in 2022 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2021 and 2022: Long-Term Investments surged 962.51% in 2021, then tumbled 72.25% in 2022.
• Over 4 years, Long-Term Investments stood at $15.6 million in 2019, then plunged by 63.8% to $5.6 million in 2020, then jumped by 1118.35% to $68.8 million in 2021, then slumped by 69.91% to $20.7 million in 2022.
• According to Business Quant data, Long-Term Investments over the past three periods registered $20.7 million, $68.8 million, and $64.3 million for Q1 2022, Q4 2021, and Q3 2021 respectively.